These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 11342630)

  • 1. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity.
    McCall AM; Shahied L; Amoroso AR; Horak EM; Simmons HH; Nielson U; Adams GP; Schier R; Marks JD; Weiner LM
    J Immunol; 2001 May; 166(10):6112-7. PubMed ID: 11342630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis.
    McCall AM; Adams GP; Amoroso AR; Nielsen UB; Zhang L; Horak E; Simmons H; Schier R; Marks JD; Weiner LM
    Mol Immunol; 1999 May; 36(7):433-45. PubMed ID: 10449096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format.
    Shahied LS; Tang Y; Alpaugh RK; Somer R; Greenspon D; Weiner LM
    J Biol Chem; 2004 Dec; 279(52):53907-14. PubMed ID: 15471859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210.
    Watanabe M; Wallace PK; Keler T; Deo YM; Akewanlop C; Hayes DF
    Breast Cancer Res Treat; 1999 Feb; 53(3):199-207. PubMed ID: 10369066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells.
    Keler T; Graziano RF; Mandal A; Wallace PK; Fisher J; Guyre PM; Fanger MW; Deo YM
    Cancer Res; 1997 Sep; 57(18):4008-14. PubMed ID: 9307286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
    Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
    J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of antibody-dependent cellular cytotoxicity by IgG intrinsic and apparent affinity for target antigen.
    Tang Y; Lou J; Alpaugh RK; Robinson MK; Marks JD; Weiner LM
    J Immunol; 2007 Sep; 179(5):2815-23. PubMed ID: 17709495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
    Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
    Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
    Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
    J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.
    Xie Z; Guo N; Yu M; Hu M; Shen B
    J Immunol Methods; 2005 Jan; 296(1-2):95-101. PubMed ID: 15680154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A trivalent anti-erbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells.
    Xie Z; Shi M; Feng J; Yu M; Sun Y; Shen B; Guo N
    Biochem Biophys Res Commun; 2003 Nov; 311(2):307-12. PubMed ID: 14592414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tribody [(HER2)
    Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
    Front Immunol; 2018; 9():814. PubMed ID: 29725336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
    Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
    Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
    Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
    Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antitumor effect of a trivalent bispecific antibody targeting ErbB2 and CD16.
    Lu H; Shi M; Wang M; Xie Z; Hu M; Yu M; Shen B; Ma Y; Guo N
    Cancer Biol Ther; 2008 Nov; 7(11):1744-50. PubMed ID: 18787406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
    Adams GP; Schier R; Marshall K; Wolf EJ; McCall AM; Marks JD; Weiner LM
    Cancer Res; 1998 Feb; 58(3):485-90. PubMed ID: 9458094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
    Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
    J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.